Advanced Magnetic Resonance Imaging Measures of Repair in Alemtuzumab Treated Patients
Multiple Sclerosis (MS) is an inflammatory demyelinating disease of the Central Nervous
System (CNS). There are many forms of MS; although the majority are Relapsing Remitting
(RRMS) representing approximately 80% of the cases. The disease appears to be more
inflammatory in RRMS as manifested by an increase in Gadolinium (Gd) enhancement on MRI and
an increase in inflammatory bio-assay markers.
Alemtuzumab; a humanized monoclonal antibody that targets the CD52 molecule present on T and
B lymphocytes, natural killer (NK) cells, and monocytes and macrophages; effects rapid and
sustained lymphocyte depletion and is approved for the treatment of B-cell chronic
lymphocytic leukemia in many countries under the names CAMPATH or MabCAMPATH.
There are two parts to this Investigator Sponsored Trial (IST):
1. To perform advanced serial MRI studies on patients initiating alemtuzumab therapy.
2. To provide serum samples for the University of Southern California (USC) ICAM125
lymphocyte recovery study.
Interventional
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Changes in normal appearing white matter from baseline through month 24.
The MRI study is designed to identify possible mechanisms by which alemtuzumab acts to protect the brain from inflammation and how it may enhance repair through remyelination.
24 months
No
Anthony Traboulsee, MD
Principal Investigator
University of British Columbia
Canada: Health Canada
H10-02482
NCT01307332
March 2011
February 2018
Name | Location |
---|